Panobinostat exhibited a marked reduction in tumor growth, accompanied by inhibition of the cell cycle pathway and a decrease in cell cycle regulators like CDKN1A via in vitro cytotoxicity assays and in vivo xenograft models (Figure 6A) (61). This evidence concerns the gene CDKN1A and neoplasm.